EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore

Yanting Ouyang iD, Han Yi Lee, Fun Loon Leong, Han Jieh Tey, Vivianne Shih, Elaine Hsuen Lim, Nicholas Graves

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241293381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 10.11.2024. Verfasst von Yanting Ouyang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Services & Systems Research, Duke-NUS Medical School, Singapore. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab (Herceptin) can be administered intravenously (IV Herceptin) and subcutaneously, with similar efficacy and safety, but with differences in dosage and costs. Previous studies have evaluated the costs of both treatment approaches in the outpatient settings, but no study has compared the costs of IV Herceptin administered in outpatients with subcutaneous Herceptin administered at patients’ homes (Homecare SC Herceptin).

Objectives

This study aimed to compare the per-patient costs of Homecare SC Herceptin versus IV Herceptin administered in a healthcare institution’s outpatient setting in Singapore. Designs: We performed a model-based cost-minimization analysis to estimate and compare the per-patient annual costs associated with each treatment modality from a societal perspective.

Methods

Direct cost comprised healthcare resources utilization: drug, consumables, manpower, facility and cardiac assessment. Indirect cost was valued using a human capital approach to account for productivity lost by patients. Monte Carlo simulations with 1000 iterations were performed to account for parameter uncertainties. Costs were reported in 2023 Singapore dollars.

Results

The annual societal cost per patient receiving IV Herceptin ranged from S$64,194 to S$65,135, while for Homecare SC Herceptin, it ranged from S$25,865 to S$26,807. Homecare SC Herceptin reduced the annual cost burden by 58.8% and 59.7%, per non-metastatic and metastatic breast cancer patient, respectively. The primary cost contributor was drug therapy, comprising more than 90% of the total cost. Even when excluding the cost of drugs, Homecare SC Herceptin remained cheaper by S$1912 annually. The cost reduction is approximately 60% compared to IV Herceptin regardless of disease status, with a 100% probability that the decision to adopt Homecare SC Herceptin leads to cost savings in Singapore.

Conclusion

Treatment of breast cancer with Homecare SC Herceptin is a cost-saving option compared to IV Herceptin.

Schlagwörter

Stichwörter der Autor:innen

HER2+ breast canceradjuvant chemotherapybreast cancerchemotherapycost-effectiveness analysishealth economicshealth services research

Autor:innen und Institutionen

  • Health Services & Systems Research, Duke-NUS Medical School, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Department of Pharmacy, National Cancer Centre Singapore, Singapore.
  • Health Services & Systems Research, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

ORCID-Profile: Yanting Ouyang

Zitieren

APA

Ouyang, Y., Lee, H. Y., Leong, F. L., Tey, H. J., Shih, V., Lim, E. H., & Graves, N. (2024). Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241293381

Vancouver

Ouyang Y, Lee HY, Leong FL, Tey HJ, Shih V, Lim EH, et al. Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241293381

BibTeX
@article{Ouyang2024,
  author = {Ouyang, Yanting and Lee, Han Yi and Leong, Fun Loon and Tey, Han Jieh and Shih, Vivianne and Lim, Elaine Hsuen and Graves, Nicholas},
  title = {Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241293381}
}
Kostenlos starten →